Canadian Cancer Trials Group Bulletins

Trial Management Group


Trials Closed to Accrual

Canadian Cancer Trials Group MA.22 -- A Phase I/II Study of Increasing Doses of Epirubicin and Docetaxel Plus Pegfilgrastim for Locally Advanced Or Inflammatory Breast Cancer -- was closed to accrual on 8 June 2009.
http://www.ctg.queensu.ca/trials/breast/ma22/ma22.html